In the search for an immunotherapy for B-cell malignancies, the membrane protein CD20 was considered a prime target. CD20 is found on the surface of all normal B cells and on 95% of cancerous B cells.

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...

ALETA-001 comprises distinct binding domains: one from the CD19 protein that allows detection by any anti-CD19 CAR T cell; and an anti-CD20 antibody fragment. Together these domains comprise the ...

One form of therapy involves labeling the CD20 protein on the surface of the B cells with customized antibodies. This triggers a chain of immunological reactions and ultimately leads to the ...

Over 50% of all drugs on the market today comprise human multi-pass transmembrane proteins, which include CD20, G Protein-coupled receptors (GPCRs), ion channels, nuclear receptors, transporters ...

MS patients on anti-CD20 therapies are significantly less likely to discontinue treatment than those given other DMTs, a ...

One form of therapy involves labeling the CD20 protein on the surface of the B cells with customized antibodies. This triggers a chain of immunological reactions and ultimately leads to the ...